Dr. Hal Gunn is the founder and CEO of Qu Biologics, and has dedicated his professional life to understanding how to optimally support the body’s immune response to chronic disease. Dr. Gunn is recognized both nationally and internationally as a leader in the field of supportive cancer care, and is the founder and past-CEO of InspireHealth, Canada’s leading supportive oncology centres. Dr. Gunn obtained his Doctorate of Medicine from the University of British Columbia and remains on faculty at UBC’s School of Medicine.

If you or someone you know is living with active Crohn’s disease which is not under control with current treatment, Qu Biologics is enrolling Canadian residents in a study to assess effectiveness of its novel Crohn’s disease therapy, QBECO Site Specific Immunomodulator (SSI). Rather than suppressing inflammation and immune function like current Crohn’s disease treatments, QBECO SSI is designed to boost and restore innate immune function. The study is open to Canadian residents with active Crohn’s disease. The treatment period is 1 year. By treating Crohn’s disease in this different way, QBECO SSI is designed to potentially achieve sustained remission off of medications and this study is designed to assess this. To learn more about QBECO and the study, please click on this link. https://www.quibd.com/